Peter Hokland

Summary

Affiliation: Aarhus University Hospital
Country: Denmark

Publications

  1. doi Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation
    Peter Hokland
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 158:569-80. 2012
  2. doi Towards individualized follow-up in adult acute myeloid leukemia in remission
    Peter Hokland
    Department of Haematology, Aarhus University Hospital, Denmark
    Blood 117:2577-84. 2011
  3. ncbi [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences]
    Peter Hokland
    Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK 8000 Arhus C
    Ugeskr Laeger 171:232-5. 2009
  4. ncbi [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]
    Peter Hokland
    Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK 8000 Arhus C
    Ugeskr Laeger 171:229-31. 2009
  5. ncbi The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML
    Mike Zangenberg
    Department of Haematology, Aarhus University Hospital, 8000 Aarhus C, Denmark
    Eur J Haematol 83:439-48. 2009
  6. doi Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias
    Hans Beier Ommen
    Laboratory of Immunohematology, Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
    Blood 115:198-205. 2010
  7. ncbi Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling
    Lene Hyldahl Olesen
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 131:457-67. 2005
  8. ncbi Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia
    Lykke Grubach
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 81:112-22. 2008
  9. doi Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals
    Hans Beier Ommen
    The Laboratory of Immunohematology, Department of Haematology, Arhus University Hospital, Arhus, Denmark
    Br J Haematol 141:782-91. 2008
  10. ncbi Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients
    Anni Aggerholm
    Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 76:23-32. 2006

Collaborators

Detail Information

Publications37

  1. doi Sensitivity of minimal residual disease in acute myeloid leukaemia in first remission--methodologies in relation to their clinical situation
    Peter Hokland
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 158:569-80. 2012
    ..Here we will attempt to give an overview of these pertinent questions intended for the practicing haematologist, focusing on where the field is heading at the clinical level...
  2. doi Towards individualized follow-up in adult acute myeloid leukemia in remission
    Peter Hokland
    Department of Haematology, Aarhus University Hospital, Denmark
    Blood 117:2577-84. 2011
    ....
  3. ncbi [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences]
    Peter Hokland
    Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK 8000 Arhus C
    Ugeskr Laeger 171:232-5. 2009
    ..A special point in favour of the techniques is the powerful and early detection of disease relapses, in some cases up to one year prior to clinical detection...
  4. ncbi [Minimal residual disease in malignant diseases of the blood I. Background and pre-clinical validation]
    Peter Hokland
    Immunhaematologisk Laboratorium, Haematologisk Afdeling R, Arhus Universitetshospital, Arhus Sygehus, DK 8000 Arhus C
    Ugeskr Laeger 171:229-31. 2009
    ..The sensitivity of quantitative polymerase chain reaction typically reaches a validated identification of 1 malignant cell in 100,000...
  5. ncbi The combined expression of HOXA4 and MEIS1 is an independent prognostic factor in patients with AML
    Mike Zangenberg
    Department of Haematology, Aarhus University Hospital, 8000 Aarhus C, Denmark
    Eur J Haematol 83:439-48. 2009
    ..In conclusion, our data show that the combination of low HOXA4 and low MEIS1 gene expression is a favourable predictor for outcome in all AML patients and that the expression levels are governed by the methylation state of these genes...
  6. doi Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias
    Hans Beier Ommen
    Laboratory of Immunohematology, Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
    Blood 115:198-205. 2010
    ..These data carry important implications for the development of optimal RQ-PCR monitoring schedules suitable for evaluation of minimal residual disease-directed therapies in future clinical trials...
  7. ncbi Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation, and selective gene expression profiling
    Lene Hyldahl Olesen
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 131:457-67. 2005
    ....
  8. ncbi Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia
    Lykke Grubach
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 81:112-22. 2008
    ..01). In conclusion, our data suggest that the role of PcG and PcG-regulated genes in leukaemogenesis varies between, as well as within karyotypic subgroups...
  9. doi Relapse prediction in acute myeloid leukaemia patients in complete remission using WT1 as a molecular marker: development of a mathematical model to predict time from molecular to clinical relapse and define optimal sampling intervals
    Hans Beier Ommen
    The Laboratory of Immunohematology, Department of Haematology, Arhus University Hospital, Arhus, Denmark
    Br J Haematol 141:782-91. 2008
    ..In conclusion, CR1 WT1 expression is an independent prognostic factor in AML. According to our model, BM is superior for relapse prediction, but PB samples are useful when shorter sampling intervals are possible...
  10. ncbi Promoter hypermethylation of p15INK4B, HIC1, CDH1, and ER is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients
    Anni Aggerholm
    Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 76:23-32. 2006
    ..05). These data suggest that hypermethylation of p15INK4B, HIC1, CDH1, and ER contribute to the development and outcome of MDS...
  11. doi Mitochondrial cytochrome c oxidase subunit II variations predict adverse prognosis in cytogenetically normal acute myeloid leukaemia
    Trine Silkjaer
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 91:295-303. 2013
    ....
  12. doi hMICL and CD123 in combination with a CD45/CD34/CD117 backbone - a universal marker combination for the detection of minimal residual disease in acute myeloid leukaemia
    Anne S Roug
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 164:212-22. 2014
    ..Finally, in post induction samples, hMICL/CD123 LAIPs were strongly correlated (r = 0·676, P = 0·0008) to applied qPCR targets. We conclude the hMICL/CD123-based MFC assay is a promising MRD tool in AML. ..
  13. ncbi Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts
    Anita Rethmeier
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 133:276-83. 2006
    ..01). Our data suggest that RARbeta2 promoter methylation is frequent in AML and may co-operate with the expression of CBF-MYH11 fusion transcripts in leukaemogenesis...
  14. ncbi Minimal residual core binding factor AMLs by real time quantitative PCR--initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse
    Jesper Stentoft
    Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, DK 8000 Aarhus C, Denmark
    Leuk Res 30:389-95. 2006
    ..This direct comparison between the two subgroups of CBF AMLs delineates clear biological differences and corroborates the value of RQ-PCR...
  15. ncbi Prospective application of a multiplex reverse transcription-polymerase chain reaction assay for the detection of balanced translocations in leukaemia: a single-laboratory study of 390 paediatric and adult patients
    Lene Hyldahl Olesen
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 127:59-66. 2004
    ....
  16. doi Persistent altered fusion transcript splicing identifies RUNX1-RUNX1T1+ AML patients likely to relapse
    Hans B Ommen
    Laboratory of Immunohematology, Department of Hematology, Aarhus University Hospital, Arhus, Denmark
    Eur J Haematol 84:128-32. 2010
    ..In conclusion, alternative splicing seems to be part of the leukemogenic process in the majority of RUNX1-RUNX1T1-positive AML patients, and splice variant kinetics under cytoreduction may be a predictor for patients prone to relapse...
  17. ncbi Relapse kinetics in acute myeloid leukaemias with MLL translocations or partial tandem duplications within the MLL gene
    Hans B Ommen
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 165:618-28. 2014
    ..In conclusion, in this cohort relapse kinetics is heavily dependent on AML subtype as well as additional genetic aberrations, with possibly great consequences for the rational choice of pre-emptive therapies. ..
  18. doi Characterization and prognostic significance of mitochondrial DNA variations in acute myeloid leukemia
    Trine Silkjaer
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 90:385-96. 2013
    ..This observation was confirmed in another cohort of 173 diagnostic AML samples. In this expanded group, the T16311C variation tended to be associated with chromosomal abnormalities...
  19. doi A patient with a 20-year lag phase between JAK2-V617F+ myeloproliferation and NPM1-mutated AML arguing against a common origin of disease
    Anne Stidsholt Roug
    Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, Aarhus C, Denmark
    Eur J Haematol 87:461-3. 2011
    ..The 20-yr lag phase between the polycythemia vera and the AML adds indirect evidence to the growing realization that the leukemic transformation in patients with MPN occurs from in a JAK2 wild-type stem cell...
  20. doi Genetic and epigenetic similarities and differences between childhood and adult AML
    Caroline Juhl-Christensen
    Department of Hematology, Aarhus University Hospital, Skejby, Denmark
    Pediatr Blood Cancer 58:525-31. 2012
    ..We addressed the combined consequences of promoter hypermethylation of p15, CDH1, ER, MDR1, and RARB2 and mutation of NPM1, CEBPA, FLT3, and WT1 in a Danish cohort of 70 pediatric and 383 adult AML patients...
  21. ncbi Cell sorting enables interphase fluorescence in situ hybridization detection of low BCR-ABL1 producing stem cells in chronic myeloid leukaemia patients beyond deep molecular remission
    Peter B van Kooten Niekerk
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 164:53-60. 2014
    ....
  22. ncbi A real-time quantitative RT-PCR assay for monitoring DEK-CAN fusion transcripts arising from translocation t(6;9) in acute myeloid leukemia
    Mette Østergaard
    Department of Hematology, Aarhus University Hospital, Tage Hansens Gade 2, 8000 C, Denmark
    Leuk Res 28:1213-5. 2004
    ..This assay should enable the widespread longitudinal minimal residual disease (MRD) follow-up in this rare subgroup of AML patients, thus adding to our knowledge of its course...
  23. doi A highly sensitive and specific qPCR assay for quantification of the biomarker SOX11 in mantle cell lymphoma
    Kristiane Hornung Hamborg
    Laboratory of Immunohaematology, Aarhus University Hospital, Denmark
    Eur J Haematol 89:385-94. 2012
    ..We hypothesised that SOX11 could be a robust molecular biomarker for MCL...
  24. ncbi Delineation of known and new transcript variants of the SETMAR (Metnase) gene and the expression profile in hematologic neoplasms
    Dinisha Cyril Jeyaratnam
    Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
    Exp Hematol 42:448-456.e4. 2014
    ..To our knowledge, this is the first study that describes an expression profile of SETMAR in subgroups of hematologic malignancies, which can be linked to the incidence of chromosomal rearrangements. ..
  25. doi Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up
    Hanne Ø Larsen
    Department of Hematology, The Laboratory of Immunohematology, Aarhus University Hospital, Aarhus, Denmark
    Cytometry B Clin Cytom 82:3-8. 2012
    ..Based on data from stem cell research, we hypothesized that the human inhibitory C-type lectin like receptor (hMICL) might represent a novel diagnostic and prognostic vehicle in a standard flow cytometry (FCM) setting...
  26. ncbi Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL
    Lene Hyldahl Olesen
    Department of Hematology, Aarhus University Hospital, Denmark
    Eur J Haematol 75:185-92. 2005
    ..More patients are needed to determine whether coduplication has independent clinical implications compared to patients with single ITD/PTD...
  27. doi Unraveling stem cell and progenitor subsets in autologous grafts according to methods of mobilization: implications for prediction of hematopoietic recovery
    Anne Stidsholt Roug
    Aarhus University Hospital, Department of Hematology, Aarhus, Denmark
    Cytotherapy 16:392-401. 2014
    ..Paired samples of G+P patients and prior insufficient G mobilization were available for analyses...
  28. ncbi Multiplex PCR for the detection of BCL-1/IGH and BCL-2/IGH gene rearrangements--clinical validation in a prospective study of blood and bone marrow in 258 patients with or suspected of non-Hodgkin's lymphoma
    Charlotte G Nyvold
    Department of Haematology, Aarhus University Hospital, Denmark
    Acta Oncol 46:21-30. 2007
    ..We conclude that this multiplex approach allows for easy and sensitive molecular determination of molecular lesions in NHL, which have diagnostic and prognostic importance...
  29. ncbi Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation
    Annette Vangsted
    Department of Haematology, Herlev University Hospital of Copenhagen, DK 2730 Herlev, Denmark
    Int J Cancer 120:1036-45. 2007
    ..0002). This indicates that suboptimal repair of both DNA mechanisms favors prolonged TTF and that polymorphism in ERCC2, XRCC3 and CD3EAP predicts the outcome for patients treated with autologous stem cell transplantation...
  30. doi Capillary gel electrophoresis: a simple method for identification of mutations and polymorphisms in the CEBPA gene in patients with acute myeloid leukaemia
    Caroline Juhl-Christensen
    Laboratory of Immunohematology, Department of Hematology, Aarhus University Hospital, Aarhus, Denmark
    Eur J Haematol 81:273-80. 2008
    ..Eight percentage of all AML patients harbour at least one mutation in this gene, increasing up to 15% in the group, where standard karyotypic analysis do not reveal chromosomal aberrations...
  31. ncbi Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas
    Camilla Darum Sørensen
    Department of Haematology, Aarhus University Hospital, Tage Hansens Gade 2, 8000 Aarhus C, Denmark
    J Immunol Methods 406:131-6. 2014
    ..The present assays could prove as useful tools in lymphoma therapy. ..
  32. doi Nonviral transfection of leukemic primary cells and cells lines by siRNA-a direct comparison between Nucleofection and Accell delivery
    Hanne Østergård Larsen
    Department of Hematology, Aarhus University Hospital, Denmark
    Exp Hematol 39:1081-9. 2011
    ..Our results reveal that Accell delivery is suitable for nonviral transfection of cells in suspension, including primary leukemic cells. These data should provide a platform for further studies of genes involved in early leukemogenesis...
  33. ncbi Prediction of target CD34 positive cells following leukopheresis in children with neuroblastoma
    Henrik Schroeder
    Department of Pediatrics, University Hospital of Aarhus, Aarhus, Denmark
    Pediatr Blood Cancer 46:786-92. 2006
    ..In children it is important to be able to ascertain when to start the leukopheresis in order to keep the number of procedures to a minimum...
  34. doi Increased expression of CD69 on T cells as an early immune marker for human cytomegalovirus reactivation in chronic lymphocytic leukemia patients
    Charlotte C Petersen
    Department of Medical Microbiology and Immunology, Aarhus University, Aarhus, Denmark
    Viral Immunol 24:165-9. 2011
    ..Moreover, a CD4(+):CD8(+) ratio lower than 0.6 may indicate a trend toward an increased risk for viral reactivation. In conclusion, an increase in CD69 expression is a promising candidate as an early predictor of HCMV reactivation...
  35. ncbi WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study
    Mette Østergaard
    Department of Haematology, Aarhus University Hospital, Aarhus, Denmark
    Br J Haematol 125:590-600. 2004
    ..We conclude that WT1 expression by RQ-PCR may be employed as a tool to detect MRD in the majority of fusion transcript-negative AML patients...
  36. ncbi Recurrent genomic imbalances in B-cell splenic marginal-zone lymphoma revealed by comparative genomic hybridization
    Claus L Andersen
    Department of Hematology, Laboratory of Cancer Cytogenetics, Arhus Sygehus, Tage Hansens Gade 2, DK 8000 Arhus C, Denmark
    Cancer Genet Cytogenet 156:122-8. 2005
    ..Our data suggest that SMZL constitute a genetically heterogeneous disease where gain of 3q25 and loss of 7q31 are the most likely imbalances to be involved in the pathogenesis of the disease...
  37. ncbi Changing picture of cellular drug resistance in human leukemia
    Jan Maxwell Nørgaard
    Department of Hematology, Aarhus University Hospital, DK 8000 Aarhus C, Denmark
    Crit Rev Oncol Hematol 50:39-49. 2004
    ..To what extent drug resistance towards this novel compound (and its successors) will follow patterns of drug resistance that are already known or entirely new mechanisms of drug resistance is yet to be seen...